CN111632040A - Manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method and application thereof - Google Patents
Manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method and application thereof Download PDFInfo
- Publication number
- CN111632040A CN111632040A CN202010556466.5A CN202010556466A CN111632040A CN 111632040 A CN111632040 A CN 111632040A CN 202010556466 A CN202010556466 A CN 202010556466A CN 111632040 A CN111632040 A CN 111632040A
- Authority
- CN
- China
- Prior art keywords
- titanium dioxide
- mesoporous titanium
- manganese dioxide
- loaded
- coated drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention belongs to the field of medical drugs, and particularly relates to manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles and a preparation method and application thereof. The preparation method of the nanoparticle comprises the following steps: firstly, a solvothermal method is utilized, the reaction temperature and time are controlled, mesoporous titanium dioxide is prepared, then, a manganese dioxide shell layer is wrapped by an oxidation-reduction reaction of potassium permanganate, and finally, drugs are loaded through electrostatic adsorption. The nanoparticles have the advantages of low cost, good stability, good biocompatibility and the like, can generate active oxygen and NO under the action of in vitro ultrasound, realize the combined application of an acoustic kinetic therapy and an NO therapy, and further generate peroxynitrite with stronger cytotoxicity by the active oxygen and the NO, thereby enhancing the tumor killing effect.
Description
Technical Field
The invention belongs to the field of medical drugs, and particularly relates to manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles and a preparation method and application thereof.
Background
Tumors become an important factor threatening the life and health of people, and the common treatment method not only has poor treatment effect, but also has serious side effect. There is therefore an urgent need to develop safer and more effective treatments.
The sonodynamic therapy is a novel tumor treatment method, and mainly takes effect through the synergy of ultrasonic waves and a sonosensitizer. The ultrasound can penetrate deep tissue to excite the sonosensitizer reaching the tumor site, which transfers energy to surrounding oxygen molecules to generate living tissueSex oxygen, including singlet oxygen (1O2), hydroxyl radical (. OH) and superoxide anion (O)2 -) Thereby generating cytotoxicity and killing tumor cells. The sonodynamic therapy has very little damage to normal tissues near the tumor and has very obvious advantages in the aspect of non-invasive treatment of deep tumors.
The titanium dioxide nanoparticles are an inorganic sound-sensitive agent, have a unique energy band structure and relatively high chemical/physiological stability, and can generate active oxygen through ultrasonic radiation so as to induce tumor cell apoptosis. The mesoporous titanium dioxide nanoparticle is a titanium dioxide nanoparticle with rich pore channels, has the excellent functions of low cost, no environmental pollution, good stability, biocompatibility and the like, and can load medicines or other substances in the pore channels to be conveyed to tumor parts. The combined application of other therapies and the sonodynamic therapy is realized.
NO is a multifunctional, dose-dependent cell signaling molecule that forms nitrite in vivo and exhibits diverse pharmacological effects in diverse physiological processes (wound healing, neurotransmitters, vasodilation, killing parasites and tumor cells, etc.). It is believed that NO is a therapeutic enhancer that enhances the sensitivity of conventional cancer therapies, possibly because high levels (μ M levels) of NO combine with superoxide anions to form oxygen free radicals that damage DNA, or because high levels of NO activate p53 and caspases, thereby modulating apoptosis and inhibiting tumor.
Arginine is the basic unit of protein and is one of the 21 amino acids that make up human proteins. It is an essential component of the human body and plays a role as a constituent of the human body. In the human body, L-arginine and oxygen are catalyzed by nitric oxide synthase to generate NO and L-citrulline. In vitro and in vivo, L-arginine can also be used as NO donor to react with active oxygen to generate NO. NO and active oxygen can react to generate peroxynitrite with stronger cytotoxicity, thereby achieving the effect of killing tumor cells. Peroxynitrite is more cytotoxic than NO and has a relatively long in vivo residence time.
Manganese dioxide, as a new inorganic material, has been rapidly developed in the field of integrated drug delivery systems for diagnosis and treatment and drug delivery. Manganese dioxide can realize biological controllable degradation in a tumor microenvironment under the conditions of low pH and high H2O2 concentration, and can raise the pH of a tumor part to generate oxygen, thereby achieving the purpose of enhancing the treatment effect by combining with the sonodynamic therapy.
Disclosure of Invention
The invention aims to solve the problems of the traditional tumor therapy, and provides manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles and a preparation method thereof, which can be used for the combined application of an acoustic dynamic therapy and an NO therapy. The manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle takes mesoporous titanium dioxide as a carrier, the carrier has acoustic dynamic characteristics, active oxygen can be generated under the action of ultrasound, loaded L-arginine can generate NO under the action of the active oxygen, and therefore the nanoparticle can directly inhibit tumors, can also generate peroxynitrite with stronger cytotoxicity with the active oxygen, and enhances the killing effect on the tumors. The manganese dioxide shell layer with the modified surface can relieve the phenomenon of aggravation of cell hypoxia caused by the acoustic dynamic therapy and improve the curative effect of the acoustic dynamic therapy.
The invention aims to provide a manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle, and a preparation method and application thereof.
The manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle comprises a mesoporous titanium dioxide nanoparticle, a manganese dioxide shell layer coating the mesoporous titanium dioxide and a loaded drug.
Further, the manganese dioxide-coated mesoporous titanium dioxide nanoparticles are loaded with L-arginine to form manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles.
Further, the diameter of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle is 40-500 nm.
The preparation method of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle comprises the following steps:
step (1): at room temperature, a small amount of tetraethyl titanate was slowly added to a quantity of glacial acetic acid and stirred to mix well. Then adding a proper amount of water to initiate the hydrolysis of the tetraethyl titanate, and reacting for 10 min. Transferring the solution into a stainless steel reaction kettle lined with polytetrafluoroethylene, placing the stainless steel reaction kettle at 150 ℃ for reaction for 12 hours, and carrying out solvent heat treatment. Cooling to room temperature, centrifuging, washing for three times, and drying to obtain the mesoporous titanium dioxide nanoparticles.
Step (2): and (2) dispersing the mesoporous titanium dioxide nanoparticles prepared in the step (1) by using deionized water, adding a certain amount of potassium permanganate under a dark condition, stirring to fully mix the potassium permanganate, adding a small amount of polyacrylamide hydrochloride solution, continuously fully stirring, centrifuging, washing for three times, and freeze-drying to obtain manganese dioxide-coated mesoporous titanium dioxide nanoparticles.
And (3): weighing a proper amount of L-arginine and the manganese dioxide-coated mesoporous titanium dioxide nanoparticles obtained in the step (2), fully dispersing with deionized water, fully stirring, centrifuging, and washing for three times to obtain manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles.
As a further improvement of the invention, the step (2) is specifically as follows: adding potassium permanganate and the mesoporous titanium dioxide obtained in the step (1) into deionized water according to the mass ratio of 5:1, magnetically stirring for 10min, adding polyacrylamide hydrochloride and the solution according to the mass ratio of the potassium permanganate to the polyacrylamide hydrochloride to 1:1-3, magnetically stirring for 10-30min, washing precipitates with deionized water for three times after centrifugation, and freeze-drying to obtain the manganese dioxide-coated mesoporous titanium dioxide nanoparticles.
As a further improvement of the invention, the step (3) is specifically as follows: and (3) adding the manganese dioxide-coated mesoporous titanium dioxide nanoparticles obtained in the step (2) and L-arginine into deionized water according to the mass ratio of 1:10-15, stirring and adsorbing for 12-24h, centrifuging, and washing the precipitate with deionized water for three times to obtain the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles.
The invention prepares mesoporous titanium dioxide by a hydrothermal method, further successfully prepares the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle, and has the excellent functions of low cost, no environmental pollution, good stability and biocompatibility, improvement of tumor microenvironment and the like.
The invention has the advantages that:
(1) the preparation method of the mesoporous titanium dioxide nanoparticles provided by the invention has the advantages of small particle size, rich pore structure, higher stability and better dispersibility, can be used as a sound-sensitive agent, can also realize the loading of various antitumor drugs, and can kill tumor cells better.
(2) The manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles provided by the invention adopt ultrasonic irradiation with good tissue penetration depth, realize the combined application of an acoustic dynamic therapy and an NO therapy, and enhance the killing effect on tumor cells.
(3) According to the invention, the manganese dioxide is used for wrapping the mesoporous titanium dioxide nanoparticles, so that the tumor hypoxia microenvironment can be improved, and the acoustic dynamic treatment effect can be improved.
Drawings
FIG. 1 is an appearance diagram of manganese dioxide coated drug-loaded mesoporous titanium dioxide nanoparticles
FIG. 2 is a transmission electron microscope image of manganese dioxide coated drug-loaded mesoporous titanium dioxide nanoparticles
FIG. 3 is a particle size distribution diagram of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
FIG. 4 is a diagram showing in vitro active oxygen generation of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
FIG. 5 is a diagram showing in vitro NO generation of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
FIG. 6 is a diagram of in vitro peroxynitrite generation of manganese dioxide coated drug loaded mesoporous titanium dioxide nanoparticles
Detailed Description
The present invention will be described in detail below with reference to the embodiments shown in the drawings, but the present invention is not limited to the embodiments.
Example 1 preparation of mesoporous titanium dioxide nanoparticles
Titanium dioxide is prepared by a hydrothermal method. At room temperature, 1ml of tetrabutyltitanate was dropped into 15ml of glacial acetic acid, and thoroughly mixed with glacial acetic acid. Then, 0.5ml of deionized water is rapidly added to initiate hydrolysis of tetrabutyl titanate, the rotating speed of magnetic stirring is increased, the reaction lasts for 10 minutes, and the solution turns milky white. Transferring the solution to a stainless steel reaction kettle lined with polytetrafluoroethylene, placing the reaction kettle in an oven to react for 12 hours at the temperature of 150 ℃, naturally cooling to room temperature, centrifugally collecting precipitate, and washing with deionized water for three times to obtain the mesoporous titanium dioxide nanoparticles.
Example 2 preparation of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
Weighing 10mg of mesoporous titanium dioxide nanoparticles, ultrasonically dispersing in a water bath, adding 50mg of potassium permanganate under the condition of keeping out of the sun, stirring for 5min to fully mix, then adding 1ml of polyacrylamide hydrochloride solution (50mg), continuously stirring for 10min, centrifuging, washing for three times, and freeze-drying to obtain the manganese dioxide-coated mesoporous titanium dioxide nanoparticles. Weighing 10mg of manganese dioxide-coated mesoporous titanium dioxide nanoparticles and 100mg of L-arginine, fully dissolving and dispersing with deionized water, continuously stirring at room temperature for 12 hours, and centrifuging to collect precipitate.
Example 3 preparation of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
Weighing 10mg of mesoporous titanium dioxide nanoparticles, ultrasonically dispersing in water bath, adding 50mg of potassium permanganate under the condition of keeping out of the sun, stirring for 5min to fully mix, then adding 1ml of polyacrylamide hydrochloride solution (100mg), continuously stirring for 20min, centrifuging, washing for three times, and freeze-drying to obtain the manganese dioxide-coated mesoporous titanium dioxide nanoparticles. Weighing 10mg of manganese dioxide-coated mesoporous titanium dioxide nanoparticles and 100mg of L-arginine, fully dissolving and dispersing with deionized water, continuously stirring at room temperature for 12 hours, and centrifuging to collect precipitate.
Example 4 preparation of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
Weighing 10mg of mesoporous titanium dioxide nanoparticles, ultrasonically dispersing in a water bath, adding 50mg of potassium permanganate under the condition of keeping out of the sun, stirring for 5min to fully mix, then adding 1ml of polyacrylamide hydrochloride solution (150mg), continuously stirring for 30min, centrifuging, washing for three times, and freeze-drying to obtain the manganese dioxide-coated mesoporous titanium dioxide nanoparticles. Weighing 10mg of manganese dioxide-coated mesoporous titanium dioxide nanoparticles and 100mg of L-arginine, fully dissolving and dispersing with deionized water, continuously stirring at room temperature for 12 hours, and centrifuging to collect precipitate.
Example 5 preparation of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
Weighing 10mg of mesoporous titanium dioxide nanoparticles, ultrasonically dispersing in a water bath, adding 50mg of potassium permanganate under the condition of keeping out of the sun, stirring for 5min to fully mix, then adding 1ml of polyacrylamide hydrochloride solution (50mg), continuously stirring for 10min, centrifuging, washing for three times, and freeze-drying to obtain the manganese dioxide-coated mesoporous titanium dioxide nanoparticles. Weighing 10mg of manganese dioxide-coated mesoporous titanium dioxide nanoparticles and 100mg of L-arginine, fully dissolving and dispersing with deionized water, continuously stirring at room temperature for 12 hours, and centrifuging to collect precipitate.
Example 6 preparation of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
Weighing 10mg of mesoporous titanium dioxide nanoparticles, ultrasonically dispersing in a water bath, adding 50mg of potassium permanganate under the condition of keeping out of the sun, stirring for 5min to fully mix, then adding 1ml of polyacrylamide hydrochloride solution (50mg), continuously stirring for 10min, centrifuging, washing for three times, and freeze-drying to obtain the manganese dioxide-coated mesoporous titanium dioxide nanoparticles. Weighing 10mg of manganese dioxide-coated mesoporous titanium dioxide nanoparticles and 150mg of L-arginine, fully dissolving and dispersing with deionized water, continuously stirring at room temperature for 24 hours, and centrifuging to collect precipitate.
Example 6 in vitro characterization of manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
The appearance of the prepared manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle is shown in figure 1; the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle suspension is released by a certain multiple, and the shape of the suspension is observed by a transmission electron microscope, as shown in figure 2, the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle has uniform particle size and is in a shuttle shape. The particle size is measured by a laser particle size analyzer, the particle size distribution result is shown in figure 3, the particle size of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nano-particles is smaller, and the average particle size is smaller than 300 nm.
Example 7 detection of in vitro production of active oxygen by manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
The condition that the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles generate active oxygen under ultrasonic irradiation is detected by 1, 3-diphenyl isobenzofuran (DPBF). Dissolving DPBF in absolute ethyl alcohol, then adding manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle solution, uniformly mixing, and ultrasonically irradiating for different times. The absorbance value at DPBF455nm was measured using an ultraviolet-visible spectrophotometer. As shown in fig. 4, after the mixed solution of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles and DPBF is irradiated by ultrasound, the absorbance at 455nm is significantly reduced with the increase of the ultrasound time. Experimental results show that active oxygen is generated by the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles under ultrasonic irradiation, and the generation of the active oxygen is increased along with the increase of the ultrasonic irradiation time.
Example 8 detection of in vitro production of NO by manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
Dispersing the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles by using 1ml of PBS, and ultrasonically irradiating for different times. After the ultrasonic irradiation, a sample was taken out, and the amount of NO released was measured by the Griess method. As shown in fig. 5, the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle suspension can release NO under ultrasonic irradiation, and the release amount of NO increases with the increase of irradiation time.
Example 9 detection of in vitro production of peroxynitrite by manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles
Tyrosine was used to detect peroxynitrite production. Manganese dioxide-coated mesoporous titanium dioxide nanoparticles loaded with drug were buffered with 0.015M NaHCO (pH 8.2)3And 5 × 10-4M tyrosine) was prepared as a 1mg/ml dispersion. Ultrasonic irradiation was given, and the fluorescence intensity was measured. As shown in fig. 6, after ultrasonic irradiation, the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles showed a significant increase in fluorescence intensity, indicating that the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles have peroxynitrite-generating activity under ultrasonic irradiationAnd (4) obtaining.
Claims (8)
1. The manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle is characterized by comprising a mesoporous titanium dioxide nanoparticle, a manganese dioxide shell layer coating the mesoporous titanium dioxide, and a loaded drug.
2. The manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle of claim 1, wherein the loaded drug is L-arginine.
3. The manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle of claim 1, wherein the average particle size of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle is 40-500 nm.
4. A preparation method of manganese dioxide coated drug-loaded mesoporous titanium dioxide nanoparticles is characterized by comprising the following steps: the method comprises the following steps:
(1) slowly adding a proper amount of tetraethyl titanate into a certain amount of glacial acetic acid at room temperature, stirring to fully mix the tetraethyl titanate and the glacial acetic acid, then adding a proper amount of water, reacting for 10min, transferring the solution into a hydrothermal reaction kettle, reacting for 12 hours at 150 ℃, cooling to room temperature, centrifuging, washing for three times, and drying to obtain mesoporous titanium dioxide nanoparticles;
(2) dispersing the mesoporous titanium dioxide nanoparticles prepared in the step (1) by using deionized water, adding a proper amount of potassium permanganate under a dark condition, stirring to fully mix, adding a proper amount of polyallylamine hydrochloride solution, continuously stirring, centrifuging, washing for three times, and freeze-drying to obtain manganese dioxide-coated mesoporous titanium dioxide nanoparticles;
(3) weighing a proper amount of L-arginine and the mesoporous titanium dioxide nano-particles wrapped by the manganese dioxide obtained in the step (2), dispersing by using deionized water, fully stirring, centrifuging, and washing for three times to obtain the manganese dioxide wrapped drug-loaded mesoporous titanium dioxide nano-particles.
5. The preparation method of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle according to claim 4, wherein the preparation method comprises the following steps: the weight ratio of the potassium permanganate added in the step (2) to the polyallylamine hydrochloride is 1:1-3, and the magnetic stirring time is 10-30 min.
6. The preparation method of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle according to claim 4, wherein the preparation method comprises the following steps: the mass ratio of the mesoporous titanium dioxide nanoparticles wrapped by the manganese dioxide and the L-arginine added in the step (3) is 1:10-15, and the magnetic stirring time is 12-24 h.
7. The manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle of claim 1, wherein the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle can generate NO under ultrasonic irradiation.
8. The use of the manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticles of claim 1 in the preparation of a tumor treatment drug combining sonodynamic therapy with NO therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010556466.5A CN111632040A (en) | 2020-06-17 | 2020-06-17 | Manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010556466.5A CN111632040A (en) | 2020-06-17 | 2020-06-17 | Manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111632040A true CN111632040A (en) | 2020-09-08 |
Family
ID=72323079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010556466.5A Pending CN111632040A (en) | 2020-06-17 | 2020-06-17 | Manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111632040A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113509549A (en) * | 2021-06-04 | 2021-10-19 | 中山大学 | Black phosphorus nanosheet composite material and preparation method and application thereof |
| CN113546091A (en) * | 2021-09-08 | 2021-10-26 | 常州市妇幼保健院 | Titanium dioxide compound with anti-tumor effect |
| CN113941010A (en) * | 2021-10-29 | 2022-01-18 | 福州大学 | Nanoparticle for synergistic treatment with NO gas and enhanced acoustodynamic treatment effect and preparation method and application thereof |
| CN114796486A (en) * | 2022-03-21 | 2022-07-29 | 华南理工大学 | Preparation method and application of platinum/titanium dioxide @ manganese dioxide-polyethyleneimine composite anticancer nanomaterial |
| CN115120720A (en) * | 2022-07-03 | 2022-09-30 | 重庆医科大学 | Metal polyphenol network coated manganese dioxide nanoparticles and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101184510A (en) * | 2005-01-24 | 2008-05-21 | 佩尔梅托制药有限责任公司 | Methods of treating various conditions by administration of sustained release l-arginine |
| CN107670040A (en) * | 2017-10-25 | 2018-02-09 | 深圳先进技术研究院 | Gold nanometer cage manganese dioxide composite nanometer particle and its preparation method and application |
| CN108815525A (en) * | 2018-07-06 | 2018-11-16 | 重庆医科大学 | A kind of multi-functional polypyrrole cladding carries medicine mesoporous TiO 2 nanoparticle and preparation method thereof |
| CN108904471A (en) * | 2018-09-19 | 2018-11-30 | 东南大学 | Nano-medicament carrier Au/MnO2And the preparation method and application thereof |
-
2020
- 2020-06-17 CN CN202010556466.5A patent/CN111632040A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101184510A (en) * | 2005-01-24 | 2008-05-21 | 佩尔梅托制药有限责任公司 | Methods of treating various conditions by administration of sustained release l-arginine |
| CN107670040A (en) * | 2017-10-25 | 2018-02-09 | 深圳先进技术研究院 | Gold nanometer cage manganese dioxide composite nanometer particle and its preparation method and application |
| CN108815525A (en) * | 2018-07-06 | 2018-11-16 | 重庆医科大学 | A kind of multi-functional polypyrrole cladding carries medicine mesoporous TiO 2 nanoparticle and preparation method thereof |
| CN108904471A (en) * | 2018-09-19 | 2018-11-30 | 东南大学 | Nano-medicament carrier Au/MnO2And the preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 余蓉主编: "《生物化学》", 31 August 2015, 中国医药科技出版社 * |
| 张宛霞: "NO供体和乏氧抗癌药物共转运纳米递送***研究", 《中国优秀博硕士学位论文全文数据库(硕士)工程科技Ⅰ辑》 * |
| 贺大伟等主编: "《临床药物治疗学》", 31 March 2018, 天津科学技术出版社 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113509549A (en) * | 2021-06-04 | 2021-10-19 | 中山大学 | Black phosphorus nanosheet composite material and preparation method and application thereof |
| CN113546091A (en) * | 2021-09-08 | 2021-10-26 | 常州市妇幼保健院 | Titanium dioxide compound with anti-tumor effect |
| CN113941010A (en) * | 2021-10-29 | 2022-01-18 | 福州大学 | Nanoparticle for synergistic treatment with NO gas and enhanced acoustodynamic treatment effect and preparation method and application thereof |
| CN114796486A (en) * | 2022-03-21 | 2022-07-29 | 华南理工大学 | Preparation method and application of platinum/titanium dioxide @ manganese dioxide-polyethyleneimine composite anticancer nanomaterial |
| CN114796486B (en) * | 2022-03-21 | 2023-03-21 | 华南理工大学 | Preparation method and application of platinum/titanium dioxide @ manganese dioxide-polyethyleneimine composite anticancer nanomaterial |
| CN115120720A (en) * | 2022-07-03 | 2022-09-30 | 重庆医科大学 | Metal polyphenol network coated manganese dioxide nanoparticles and preparation method thereof |
| CN115120720B (en) * | 2022-07-03 | 2023-07-14 | 重庆医科大学 | Metal polyphenol network coated manganese dioxide nanoparticle and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111632040A (en) | Manganese dioxide-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method and application thereof | |
| CN108434462B (en) | Multifunctional nano diagnosis and treatment agent with mesoporous polydopamine loaded carbonyl manganese and preparation method and application thereof | |
| Yang et al. | Recent advances in nanosized metal organic frameworks for drug delivery and tumor therapy | |
| CN108815525B (en) | Multifunctional polypyrrole-coated drug-loaded mesoporous titanium dioxide nanoparticle and preparation method thereof | |
| Sun et al. | MnO 2 nanoflowers as a multifunctional nano-platform for enhanced photothermal/photodynamic therapy and MR imaging | |
| CN113751079B (en) | Perovskite-titanium dioxide nano composite photocatalyst loaded by biological material and construction method and application thereof | |
| CN111569073A (en) | Photosensitizer-loaded mesoporous Prussian blue-manganese nanoparticles and preparation method thereof | |
| CN111529510A (en) | Application of nanoparticles as tumor microenvironment responsive drug or imaging agent | |
| CN107261142B (en) | Porous carbon nanofiber-based drug-loaded photothermal reagent for tumor treatment and preparation method thereof | |
| CN109289050B (en) | Ferroferric oxide/polypyrrole/glucose oxidase composite multifunctional nano diagnosis and treatment agent and preparation method and application thereof | |
| CN112807430A (en) | Application of nano enzyme-based material | |
| Yao et al. | π–π conjugation promoted nanocatalysis for cancer therapy based on a covalent organic framework | |
| CN113559064A (en) | Novel self-oxygen-supply liposome nanoparticle and preparation method and application thereof | |
| CN109125723B (en) | Compound sound sensitive agent, preparation method, application, use method, application and pharmaceutical composition thereof | |
| Chen et al. | A Cu 2+ doped mesoporous polydopamine Fenton nanoplatform for low-temperature photothermal therapy | |
| CN113117077B (en) | Platinum-based monatomic nanoenzyme for tumor combined treatment and preparation method thereof | |
| CN110115763B (en) | Near-infrared light activated multifunctional liposome and preparation method and application thereof | |
| CN113941009A (en) | Metal organic framework nano-carrier and preparation method and application thereof | |
| CN111759808B (en) | Liposome-graphene-gold composite nano material and preparation method and application thereof | |
| CN113577306A (en) | Preparation of double-targeting pH stimulus-responsive nano particles and application of nano particles in tumor diagnosis and treatment | |
| CN110882389B (en) | Titanium monoxide nano material and preparation method and application thereof | |
| Shen et al. | A biodegradable nano-photosensitizer with photoactivatable singlet oxygen generation for synergistic phototherapy | |
| CN112546227A (en) | Preparation method of AIPH bismuth selenide loaded nanoparticles wrapped by calcium manganese phosphide | |
| CN114668841B (en) | Activatable nano photosensitizer and preparation method and application thereof | |
| CN114601925B (en) | Hyaluronic acid and RSL3 co-modified photosensitive nanomaterial, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200908 |